On our screens:Stocks with no debt
Is it safe?
Can AVLN take a bad year?
Avalyn Pharma Inc. holds $338M more cash than debt, so a bad year is a question about profits, not about lenders.
$338M
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Debt / equity
- 0.04×
Debt / equity
- Annualised volatility
- 65%
Annualised volatility · three times the market's own swing
Details›
- Total debtQ2 2026
- $15M
- Cash and short-term investments
- $352M
- Net cash
- $338M
- Debt / equity
- 0.04×
- Annualised volatilitytwo years of daily moves
- 65%
- Worst drawdown on file
- −22%
- Below its 52-week high
- 4.2%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Biotechnology
The closest names by size in the same industry